Acute Hepatic Porphyria

Gastroenterology

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic

2100%

+ 4 programs with unclassified modality

Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.

$7.3B marketMature→ Stable30 products15 companies

Key Trends

AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds

Career Verdict

Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	LINZESS (linaclotide)	AbbVie	$1.8B	25%	Peak	Stable	7.7yr
2	CREON (pancrelipase)	AbbVie	$1.5B	21%	LOE Approaching	Declining
3	XIFAXAN (rifaximin)	Bausch Health	$1.1B	15%	LOE Approaching	Declining
4	RINVOQ (upadacitinib)	AbbVie	$976M	13%	Peak	Growing	11.8yr
5	XELJANZ XR (tofacitinib)	Pfizer	$586M	8%	Peak	Stable	8.3yr

#1LINZESS

$1.8B

AbbVie·Peak7.7yr

#2CREON

$1.5B

AbbVie·LOE Approaching

#3XIFAXAN

$1.1B

Bausch Health·LOE Approaching

#4RINVOQ

$976M

AbbVie·Peak11.8yr

#5XELJANZ XR

$586M

Pfizer·Peak8.3yr

Drug Class Breakdown

Unknown Mechanism

$2.5B(34%)

mature portfolio anchor

Guanylate Cyclase Activators

$1.9B(27%)

well-established class

Pancreatic Enzymes

$1.5B(20%)

facing biosimilar competition

Janus Kinase Inhibitors

$976M(13%)

growing IBD adoption

Proton Pump Inhibitors

$107M(1%)

commoditized

Career Outlook

Stable

Gastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.

Breaking In

Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.

For Experienced Professionals

Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.

In-Demand Skills

IBD and IBS indication expertiseJAK inhibitor pharmacologyMedical device integration (diagnostics, endoscopy)Generic/biosimilar launch readinessReal-world evidence generation

Best For

Medical Science Liaison (IBD/IBS focus)Commercial Manager (Generic Launch)Clinical Operations SpecialistMarket Access/Reimbursement StrategistRegulatory Affairs (small molecule focus)

Hiring Landscape

$70K-$213K

Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.

1,818

Open Roles

Companies Hiring

Departments

Top Hiring Companies

377

323

293

By Department

Engineering(24%)

$169K

Commercial(15%)

$176K

Manufacturing(10%)

$213K

Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.

On Market (1)

Approved therapies currently available

GIVLAARIApproved

givosiran sodium

Alnylam Pharmaceuticals

subcutaneous2019

15M Part D

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Alnylam PharmaceuticalsCAMBRIDGE, MA

6 programs

GIVLAARI(givosiran)Phase 3RNA Therapeutic5 trials

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)N/A1 trial

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)N/A1 trial

Givosiran (Acute Hepatic Porphyria registry)N/ARNA Therapeutic

INSIGHT-AHP Acute Hepatic Porphyria Prevalence StudyN/A

+1 more programs

Active Trials

NCT04883905Recruiting150Est. Apr 2027

NCT02240784Completed136Est. Apr 2021

NCT04056481Approved For Marketing

+4 more trials

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Alnylam Pharmaceuticalsgivosiran

Alnylam PharmaceuticalsELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Alnylam PharmaceuticalsEXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Clinical Trials (7)

Total enrollment: 446 patients across 7 trials

NCT03338816 Alnylam Pharmaceuticalsgivosiran

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Start: Nov 2017Est. completion: May 202194 patients

Phase 3Completed

NCT02949830 Alnylam Pharmaceuticalsgivosiran

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Start: Oct 2016Est. completion: Nov 202116 patients

Phase 1/2Completed

NCT03505853 Alnylam Pharmaceuticalsgivosiran

A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

Start: Apr 2018Est. completion: Jan 201910 patients

Phase 1Completed

NCT02452372 Alnylam Pharmaceuticalsgivosiran

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Start: May 2015Est. completion: Sep 201740 patients

Phase 1Completed

NCT04056481 Alnylam Pharmaceuticalsgivosiran

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

N/AApproved For Marketing

NCT04883905 Alnylam PharmaceuticalsELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Start: Apr 2021Est. completion: Apr 2027150 patients

N/ARecruiting

NCT02240784 Alnylam PharmaceuticalsEXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Start: Aug 2014Est. completion: Apr 2021136 patients

N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 446 patients

1 companies competing in this space

Related Indications

Hepatic Impairment(157)Irritable Bowel Syndrome(76)Liver Transplantation(62)Gastroesophageal Reflux Disease(60)Gastroparesis(56)Liver Cirrhosis(48)Hepatic Insufficiency(48)Celiac Disease(45)Gastroesophageal Reflux(40)Cirrhosis(32)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.